Novavax is working to advance a potential coronavirus vaccine. So are competitors.

As the coronavirus spreads, Novavax Inc. is moving forward to find a defense against it. The Gaithersburg company, which a month ago set out to develop a vaccine for the COVID-19 coronavirus, is now evaluating candidates in animal models — a critical step toward testing in humans. Now Novavax (NASDAQ: NVAX) hopes to receive Food and Drug Administration approval to start human clinic al trials by the end of this spring, it said Wednesday, a fast timeline relative to the yearslong research and development…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news